FDA approves Merck’s Keytruda (pembrolizumab) for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, a rare form of skin cancer

19 December 2018 - Accelerated approval based on results of CITN-09/KEYNOTE-017, where Keytruda monotherapy demonstrated an objective response rate of 56%. ...

Read more →

DBV Technologies provides update on Viaskin Peanut for children four to 11 years of age

19 December 2018 - Application withdrawn following discussions with FDA regarding insufficient data on manufacturing procedures and quality controls. ...

Read more →

Lynparza approved by US FDA for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer

19 December 2018 - AstraZeneca and MSD’s Lynparza reduced the risk of disease progression or death by 70% compared to placebo ...

Read more →

More lawsuits = higher drug prices

18 December 2018 - The FDA pulls an Obama rule that was a trial-lawyer special. ...

Read more →

Equillium granted U.S. FDA fast track designation for EQ001 for the treatment of acute graft-versus-host disease

19 December 2018 - Company plans to initiate Phase 1b/2 EQUATE clinical trial in early 2019. ...

Read more →

FDA advances new scientific framework to promote greater predictability, efficiency in oncology drug development

19 December 2018 - Today, the U.S. FDA issued guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and ...

Read more →

Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score

19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...

Read more →

Establishing the effectiveness of procedural interventions: the limited role of randomised trials

18 December 2018 - Procedural interventions comprise a large and growing component of medical care. Patients, physicians, health care organisations, and ...

Read more →

Cipher Pharmaceuticals announces A-101 40% topical solution accepted for review by Health Canada

18 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for A-101 40% topical solution ("A-101 40%") ...

Read more →

Warren unveils bill to lower drug prices by letting government manufacture them

18 December 2018 - Senator Elizabeth Warren has unveiled a bill aimed at lowering drug prices by allowing the government ...

Read more →

Eiger announces PRIME designation granted by European Medicines Agency for lonafarnib for treatment of hepatitis delta virus infection

18 December 2018 - Phase 3 hepatitis D virus “D-LIVR” international study initiating. ...

Read more →

Our door is open: FDA puts patients first

18 December 2018 - We believe patients are experts when it comes to their health conditions.  ...

Read more →

Statement from FDA Commissioner and Director of the Center for Devices and Radiological Health on new steps to promote innovations in medical devices that help advance patient safety

18 December 2018 - Spurring innovation of medical products so that patients can have access to safe, effective treatments that ...

Read more →

Revolutionary' cancer drug using genetically modified cells approved

19 December 2018 - A revolutionary cancer therapy that supercharges a patient's immune cells to hunt and destroy cancer cells ...

Read more →

European Commission approves Merck’s Keytruda (pembrolizumab) as adjuvant therapy for adults with resected Stage III melanoma

17 December 2018 - First approval for Keytruda in an adjuvant setting in the European Union. ...

Read more →